Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study
Top Cited Papers
Open Access
- 17 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 64 (4), 778-794
- https://doi.org/10.1007/s00125-020-05351-w
Abstract
Aims/hypothesis This is an update of the results from the previous report of the CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). Methods The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020. We mainly focused on hospital discharge and death within 28 days. Results We included 2796 participants: 63.7% men, mean age 69.7 ± 13.2 years, median BMI (25th–75th percentile) 28.4 (25.0–32.4) kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within 28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5–14) days, while 577 participants died (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and longer symptom duration on admission were positively associated with discharge. History of microvascular complications, anticoagulant routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge, and also included routine treatment by insulin and statin as deleterious factors. Conclusions/interpretation In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital discharge and death that could help clinicians in this pandemic period. Trial registration Clinicaltrials.gov identifier: NCT04324736 Graphical abstractKeywords
Funding Information
- Merck Sharp and Dohme
- Fonds de dotation du CHU de Nantes
- Fondation Francophone de Recherche sur le Diabète
- Société Francophone du Diabète
- Eli Lilly and Company
- AstraZeneca
- Novo Nordisk
- Fédération Française des Diabétiques
- Abbott Fund
This publication has 32 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Covid-19 in Critically Ill Patients in the Seattle Region — Case SeriesThe New England Journal of Medicine, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective studyEpidemiology and Infection, 2018
- Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort studyEuropean Heart Journal Acute Cardiovascular Care, 2018
- Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic AttackStroke, 2017
- Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failureCardiovascular Diabetology, 2017
- Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARSDiabetic Medicine, 2006
- Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overviewThe Lancet, 2000